Zuckerberg & Chan on AI-Driven Biology at CZI Biohub
Mark Zuckerberg and Priscilla Chan discuss the Chan Zuckerberg Initiative's decade-long effort to accelerate basic science through shared tools, data sets, and AI infrastructure rather than funding individual therapies. CZI's flagship product, the cellxgene Cell Atlas, has grown into a community resource of millions of annotated single cells, with 75% of contributions coming from external researchers who adopted the open standard and annotation tool. The bulk of the conversation centers on "virtual cell models"—a hierarchical stack spanning proteins, cells, tissues, and eventually whole immune systems—that CZI is building to let scientists de-risk hypotheses in silico before expensive wet-lab work. Zuckerberg and Chan announce that Evolutionary Scale, a company founded by former Meta protein-folding researchers, is joining the Biohub under Alex Rives, who will lead a newly unified science program. Chan argues that most diseases should be treated as rare diseases because each patient's biology is unique, and that better tools—not better treatments alone—will unlock precision medicine. They also outline the Biohub network's structure (SF for imaging, Chicago for tissue/cell communication, New York for cell engineering), a 1,000-GPU compute cluster scaling to 10,000 that is shared with outside scientists, and an early "reasoning model over biology" that aims to explain why cellular interventions succeed or fail. Zuckerberg says the end-of-century cure-disease goal may now be reachable "significantly sooner" given AI advances, and that Biohub is becoming the central focus of CZI's philanthropy going forward.
Original sources
Podcast The a16z Show
Episode:Mark Zuckerberg & Priscilla Chan: How AI Will Help Cure Disease ↗
YouTube The a16z Show
AI Radar wrote this summary from the publisher’s notes with AI, not from a transcript. How it works.